(Press-News.org) The fixed-dose drug combination ombitasvir/paritaprevir/ritonavir (trade name Viekirax) has been available since January 2015 for the treatment of adults with chronic hepatitis C infection. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this drug combination offers an added benefit over the appropriate comparator therapy.
According to the findings, there are indications of an added benefit in patients who have not yet developed cirrhosis of the liver and who are infected with the hepatitis C virus (HCV) genotype 1a. In case of genotype 1b, this only applies to treatment-naive, but not to treatment-experienced patients. The extent of added benefit is non-quantifiable, however. No added benefit can be derived from the dossier for 13 other patient groups.
Differentiated approvals result in a large number of patient groups
The new fixed-dose combination is only approved in combination with other drugs (dasabuvir and/or ribavirin). The Summaries of Product Characteristics specify partly different treatment regimens both for these drugs or drug combinations and for the respective comparator therapies. This results in as many as 16 patient groups for this benefit assessment, which mainly differ in type of virus, pretreatment and stage of disease.
Two direct comparative studies
All 16 groups were reflected in the dossier compiled by the drug manufacturer, but the data were informative for only 3 of these groups. The benefit assessment was based on two randomized controlled approval studies (MALACHITE I and II), in which ombitasvir/paritaprevir/ritonavir in combination with dasabuvir and/or ribavirin was directly compared with triple therapy consisting of telaprevir, pegylated interferon and ribavirin.
In compliance with the approval, the new fixed-dose combination was administered in the intervention arm for a period of 12 weeks, whereas treatment in the comparator arm could last up to 48 weeks, depending on response to the treatment.
Patients in the intervention arm were free of the virus more frequently
These two studies provided conclusive results for patients who have not yet developed cirrhosis of the liver and who are infected with a virus of genotype 1a or 1b. In genotype 1a, this applies both to treatment-naive patients and to patients who had relapsed after initially successful treatment. In genotype 1b, appropriate data were available only for treatment-naive patients.
In these three patient groups, the data showed a statistically significant difference in sustained virologic response (SVR) in favour of the new fixed-dose combination. IQWiG derived an indication of an added benefit from this. Its extent is non-quantifiable, however. It remained unclear in how many patients in whom the virus is no longer detectable, late complications, and liver cancer in particular, can actually be prevented.
Quality of life: advantage in treatment-naive patients
For the first time in the assessment of a hepatitis C drug, the manufacturer dossier contained evaluable data on health-related quality of life, which is of particular importance regarding interferon, which is considered to be very burdensome. These data on quality of life showed an advantage of ombitasvir/paritaprevir/ritonavir at least for the duration of treatment. This applies to certain treatment-naive genotype 1a or 1b patients, but not to treatment-experienced patients (genotype 1a). It depends on the severity of the disease whether they have an advantage and how big this advantage is.
IQWiG derived a hint of an added benefit with differing extent from these data.
Data on side effects partly not conclusively interpretable
The important differences in treatment duration between intervention and control arm, which could be up to 36 weeks, partly made it impossible to interpret differences in side effects. Since the observation periods also differed, the results were probably biased. In certain patient groups or aspects of side effects (serious adverse events and treatment discontinuation), however, the data were robust and therefore conclusions could be drawn. In each case, the results were in favour of the new fixed-dose combination.
IQWiG therefore sees a hint or an indication of lesser harm in treatment-naive genotype 1b patients and an indication of lesser harm in treatment-experienced genotype 1a patients for individual aspects of side effects. Overall, greater or lesser harm is not proven.
Robust data were lacking for further patient groups
The dossier contained no suitable data for the remaining 13 patient groups (genotype 1 or 4). Since direct comparative studies were lacking, the manufacturer referred to studies on ombitasvir/paritaprevir/ritonavir, in which the fixed-dose combination was not tested against the appropriate comparator therapy, however. No systematic comparison with data on the appropriate comparator therapy was conducted. Since there was also no systematic search for studies on the comparator therapies, it can be assumed that the data were incomplete.
Overall, an indication of a non-quantifiable added benefit can be derived from the dossier for three patient groups: patients without cirrhosis of the liver infected with genotype 1a (treatment-naive and treatment-experienced) and with genotype 1b who have not been pretreated.
G-BA decides on the extent of added benefit
This dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.
INFORMATION:
An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website » http://www.gesundheitsinformation.de, published by IQWiG, provides easily understandable German-language information.
More English-language information will be available soon (Sections 2.1 to 2.8 of the dossier assessment as well as subsequently published health information on » http://www.informedhealthonline.org). If you would like to be informed when these documents are available, please send an e-mail to » info@iqwig.de.
This news release is available in German. FRANKFURT. Scientists at the Goethe University Frankfurt and at the Senckenberg Biodiversity and Climate Research Centre working together with their Canadian counterparts, have reconstructed the climatic development of the Arctic Ocean during the Cretaceous period, 145 to 66 million years ago. The research team comes to the conclusion that there was a severe cold snap during the geological age known for its extreme greenhouse climate. The study published in the professional journal Geology is also intended to help improve prognoses ...
(Edmonton) Each year, thousands of Canadians are given the news: they have skin cancer. It is the most common form of cancer in Canada and around the world, but if detected early, survival rates are extremely high. According to Liam Rourke, it doesn't happen nearly as often as it could.
"The difficulty is that people have a really hard time detecting skin cancer melanomas early," says Rourke, an associate professor in the Faculty of Medicine & Dentistry's Department of Medicine at the University of Alberta. "One of the reasons is that it's an exceptionally difficult task ...
Investigators at Stanford University have found a surprising link between creative problem-solving and heightened activity in the cerebellum, a structure located in the back of the brain and more typically thought of as the body's movement-coordination center.
In designing the study, the researchers drew inspiration from the game Pictionary.
The cerebellum, traditionally viewed as the brain's practice-makes-perfect, movement-control center, hasn't been previously recognized as critical to creativity. The new study, a collaboration between the School of Medicine and ...
Stanford electrical engineer Jelena Vuckovic wants to make computers faster and more efficient by reinventing how they send data back and forth between chips, where the work is done.
In computers today, data is pushed through wires as a stream of electrons. That takes a lot of power, which helps explain why laptops get so warm.
"Several years ago, my colleague David Miller carefully analyzed power consumption in computers, and the results were striking," said Vuckovic, referring to electrical engineering Professor David Miller. "Up to 80 percent of the microprocessor ...
A quantum system never relaxes. An isolated system (like a cloud of cold atoms trapped in optical grids) will endlessly oscillate between its different configurations without ever finding peace. In practice, these types of systems are unable to dissipate energy in any form. This is the exact opposite of what happens in classical physics, where the tendency to reach a state of equilibrium is such a fundamental drive that is has been made a fundamental law of physics, i.e., the second law of thermodynamics, which introduces the concept of entropy.
This profound difference ...
WASHINGTON -- People who earn a college degree before getting married are much less likely to become obese than those who graduate from college after getting married, according to a new study.
"People who get married before they earn a degree from a four-year college are about 65 percent more likely to later become obese than people who get married after college," said Richard Allen Miech, a research professor at the Institute for Social Research at the University of Michigan and the lead author of the study. "While a college degree has long been shown to be associated ...
A fifty-fold between-country difference in rates of paracetamol-induced acute liver failure that leads to liver transplant (ALFT) has been revealed by a study that compared patient data from seven countries at the request of the European Medicines Agency: France, Greece, Ireland, Italy, Netherlands, Portugal and the UK. Researchers discovered that this variation was even more pronounced on a per-capita basis, with a 200-fold difference in ALFT cases. Publishing these findings in the British Journal of Clinical Pharmacology, the authors call for further research to identify ...
Several genes have been lost from the Y chromosome in humans and other mammals, according to research published in the open access journal Genome Biology. The study shows that essential Y genes are rescued by relocating to other chromosomes, and it identifies a potentially important genetic factor in male infertility.
The Y chromosome is dramatically smaller than the X chromosome and has already lost nearly all of the 640 genes it once shared with the X chromosome.
An extreme example of genes disappearing from the Y chromosome can be found in the Ryukyu spiny rat, ...
In what they believe to be the first survey of its kind in the United States, researchers at NYU Langone Medical Center have found that as many as 6 percent of adult New Yorkers who get "inked" -- in other words, those who get a tattoo -- have experienced some form of tattoo-related rash, severe itching or swelling that lasted longer than four months and, in some cases, for many years.
"We were rather alarmed at the high rate of reported chronic complications tied to getting a tattoo," says senior study investigator and NYU Langone dermatologist Marie Leger, MD, PhD, ...
Researchers from the Netherlands have explored how 3D printing can be used to help treat type 1 diabetes in results presented today, Thursday 28 May, in IOP Publishing's journal Biofabrication.
The 3D printing technique, known as bioplotting, has taken researchers one step closer to being able to help patients who experience severe hypoglycaemic events, commonly known as 'hypos'- a problem that affects about a third of people with type 1 diabetes according to Diabetes UK.
The paper describes how clusters of specialized cells responsible for the production of insulin ...
